Brought to you by 
Alcobra, Arcturus merge in reverse stock swap
10 Oct 2017
Executive Summary
Troubled Israeli biotech Alcobra Ltd. (mostly cognitive disorder therapeutics) has agreed to merge in a reverse stock swap with private US RNA-focused start-up Arcturus Therapeutics Inc. (ATI; rare diseases) to form a new company known as Arcturus Therapeutics Ltd. (ATL), in which Arcturus will have a 60% stake and Alcobra will hold the remainder. Alcobra announced in May it was looking for strategic alternatives (including partnering or M&A opportunities) to create shareholder value.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alcobra, Arcturus merge in reverse stock swap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice